Takeda Pharmaceutical Co. has agreed to buy Dublin-based Shire PLC for $62 billion in a deal announced May 8 that could affect hundreds of Shire employees in Los Angeles.
The acquisition would create the world’s eighth-largest drug maker with combined sales worth $30 billion. The deal is expected to close by the summer of 2019.
The Takeda takeover will mean lay-offs, Osaka-based Takeda said, as the companies consolidate operations.
What’s unclear is how it might affect Shire operations in Los Angeles.
A Shire plant in Atwater Village develops plasma-related treatments for hemophilia, trauma, kidney disease and immune system disorders.
Shire acquired it 2016 when it acquired Baxalta, a biopharmaceutical spinoff of Baxter International, for $32 billion. The merger also included a genomics research laboratory in Thousand Oaks.
A Business Journal ranking of the region’s largest biotechnology firms in March listed the Los Angeles’ Shire subsidiary as tied for fifth with 1,500 local workers.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Takeda Picks Up Shire for $62 Billion
- L.A. Jobs on the Line as Opponents Battle $62 Billion Takeda Buyout of Shire
- LA Jobs on the Line With Takeda Poised for EU Approval for $62B Shire Buy
- EU Approval For $62B Shire Purchase
- Arrowhead Pharmaceuticals Cuts Deal With J&J Valued at Up to $3.7B
- Drug Maker to Boost Production
- Kythera to Lay Off 117 Workers
- Amgen Signs Japanese Partner